Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) EPS (Weighted Average and Diluted) (2021 - 2025)

Valion Bio has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$2.19 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 59.22% year-over-year to -$2.19; the TTM value through Jun 2025 reached -$23.55, up 87.62%, while the annual FY2024 figure was -$19.68, 88.87% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2025 was -$2.19 at Valion Bio, up from -$2.52 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.23 in Q1 2022 and troughed at -$166.2 in Q4 2023.
  • A 5-year average of -$15.82 and a median of -$2.36 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 4861.7% in 2022 and later soared 94.52% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.47 in 2021, then plummeted by 4861.7% to -$23.32 in 2022, then plummeted by 612.69% to -$166.2 in 2023, then surged by 88.8% to -$18.61 in 2024, then soared by 88.23% to -$2.19 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TIVC at -$2.19 in Q2 2025, -$2.52 in Q1 2025, and -$18.61 in Q4 2024.